Featured

Omeza announces closing of $8.5 Million Series A financing co-led by Astanor and BluKap Ventures, with participation from Catalyst Investments

Round positions Omeza to accelerate clinical development and scale nationwide commercialization of its FDA-cleared regenerative wound care platform Sarasota, FL – April 16th, 2026 – Omeza Holdings, Inc. (“Omeza”), a commercial-stage advanced …

Omeza will be attending the upcoming Symposium on Advanced Wound Care (SAWC) Fall 2025, September 4-6, 2025

Contact cflowers@omeza.com if interested in learning more about our company. Omeza will be in attendance alongside our national distributor, Advanced Solution. About OMEZA Omeza® is a commercial-stage regenerative skin and wound-care company that develops …

Advanced Solution and Omeza Holdings Inc. Announce Exclusive National Commercialization Partnership for Revolutionary Wound Care Product, Omeza’s OCMTM

– Exclusive distribution agreement aims to expand access to cutting-edge wound care solutions nationwide. – Carlisle, PA – May 19, 2025 – Advanced Solution, a national leader in regenerative medicine distribution, is proud to …

Case Studies of Patients with Diabetic Foot Ulcers Showed 90 to 100 Percent Wound Closure at 12 weeks Following Weekly Treatment with Novel OMEZA® OCM™

–Three case studies reinforce clinical trial data demonstrating dramatic healing rates among patients with diabetic foot ulcers treated with OCM™ – CLEVELAND – June 11, 2024 – Omeza®, a regenerative skincare company …

OMEZA® CLINICAL STUDY TO EVALUATE OCM™ WOUND MATRIX FOR THE TREATMENT OF CHRONIC CUTANEOUS WOUNDS/ULCERS OF MULTIPLE ETIOLOGIES HAS COMPLETED ENROLLMENT AND FINAL DATABASE LOCK. FULL RESULTS WILL BE SUBMITTED TO A PEER REVIEW JOURNAL.

Sarasota, FL June 6, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today announced completion of a multi-center clinical study which evaluated …

NOVEL OMEZA® OCM™ WOUND MATRIX CLINICAL STUDY IN VENOUS LEG ULCERS HAS COMPLETED ENROLLMENT AND FINAL DATABASE LOCK. FULL RESULTS TO BE SUBMITTED TO PEER REVIEW JOURNAL

Sarasota, FL June 5, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today announced completion of a multi-center open label study comparing …

NOVEL OMEZA® OCM™ WOUND MATRIX DEMONSTRATES MULTIMODAL EFFECTS BY REDUCING BACTERIAL CONTAMINATION IN “STALLED”, HARD TO TREAT WOUNDS, WHILE SUPPORTING HEALING RATES

SARASOTA, Fla., May 14, 2024 /PRNewswire/– Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today announced a submission of an evaluation of OCM™ Wound …

NOVEL OMEZA® OCM™ WOUND HEALING PLATFORM COMBINED WITH OFFLOADING IN PATIENTS WITH DIABETIC FOOT ULCERS DEMONSTRATED DRAMATIC HEALING RATES WITHIN 12 WEEKS OR LESS

LONDON, May 3, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today presented final data from a diabetic foot ulcer (DFU) clinical …

Omeza Wins Top Innovation Award from Wound Journal

Wound Management & Prevention (WMP) Journal selected Omeza for a “Top Innovation in Wound Care 2022” Award for the Omeza products bundle. The Omeza treatment product line consists of the Omeza® Lidocaine …

Our Mission

Omeza Quick Links